Evidence map›Paper›PMID 42613563›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2026

A Conditional Plasmid System for Markerless Gene Deletion in Genetically Recalcitrant Fusobacterium nucleatum subsp. animalis.

Bibek G C, Chenggang Wu

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Bibek G CDepartment of Microbiology & Molecular Genetics, The University of Texas Health Science Center, Houston, TX, USA.
Chenggang WuDepartment of Microbiology & Molecular Genetics, The University of Texas Health Science Center, Houston, TX, USA. chenggang.wu@uth.tmc.edu.

Funding

Regulation in Fusobacterium-mediated coaggregationR01DE030895 · NIDCR · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI WU, CHENGGANG · 2021 to 2025
$1.7M
Study of essential genes in Fusobacterium nucleatumR21DE034542 · NIDCR · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI WU, CHENGGANG · 2024 to 2024
$429k
NIDCR NIH HHS R01 DE030895NIDCR NIH HHS R21 DE034542
6 · The paper itself

Abstract

Fusobacterium nucleatum subsp. animalis (FNA) plays a prominent role in oral microbial ecology and is increasingly implicated in systemic diseases such as colorectal cancer. However, its genetic intractability has significantly hindered functional studies to understand its pathogenic mechanisms. To address this challenge, we developed a conditional plasmid system that enables efficient, markerless gene deletion in FNA strains. This system features inducible control of plasmid replication via a theophylline-responsive riboswitch regulating repA, and counterselection via the MazF toxin under the control of an anhydrotetracycline-inducible promoter. In this chapter, we provide a detailed, step-by-step protocol for implementing this system using FNA strain 7_1 as a model. We illustrate the procedure by deleting the luxS gene, which encodes S-ribosylhomocysteine lyase-an enzyme involved in AI-2 quorum sensing and biofilm regulation. Our protocol provides a powerful and adaptable tool for advancing genetic studies in this genetically recalcitrant subspecies.

Indexed as

Fusobacterium nucleatumGene DeletionPlasmidsBacterial ProteinsCarbon-Sulfur LyasesGene Expression Regulation, BacterialPromoter Regions, GeneticQuorum SensingBacterial ProteinsCarbon-Sulfur LyasesLuxS protein, BacteriaConditional plasmidFusobacterium nucleatum subsp. animalisGene deletionLuxSmazF as a counterselection marker

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.